PURPOSE: This study aimed to evaluate the personalized dosimetric approach by calculating the cumulative renal absorbed dose (cRD) and assessing its impact on renal functions in patients diagnosed with metastatic castration-resistant prostate cancer who underwent four or more cycles of [ METHODS: The study included 110 patients who received ≥ 4 cycles of [ RESULTS: Pearson correlation analysis reveal no significant relationship between cRD and CKD-EPI values (p >
.05). No significant differences were observed between pre-treatment CKD-EPI levels and those measured after the 4th, 5th, 6th, 7th, and 8th cycles (p >
.05). Among patients reaching a cRD of 23 Gy, a statistically significant difference was observed between pre- and post-treatment CKD-EPI values (p <
.05). Of the 13 patients exceeding cRD of 28 Gy, five maintained CKD-EPI levels above 90 mL/min/1.73 m CONCLUSION: Despite treatment-related declines in eGFR levels, our findings indicate that a personalized dosimetric approach may enable extended cycles of [